DexCom, Inc. (NASDAQ:DXCM) is one of the stocks on Jim Cramer’s radar recently. A caller asked if they should buy, sell, or hold the stock during the lightning round. In response, Cramer said: “You ...

In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings. The recall affects approximately 3 million sensors and was caused by an ...

Senseonics earns a buy with Eversense 365 driving growth, Q3 revenue up 90% YoY, gross margin expansion, and Ascensia ...

GlucoModicum today unveiled Sofio, which it labels the world's first needle-free glucose monitor based on magneto-hydrodynamics (MHD).

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose ...

In 2021, she joined Roc Nation’s office operations team full-time, bringing years of institutional knowledge and loyalty with her.

TNDM's global expansion and strategic integrations fuel growth potential, even as pump reliance and macro pressures weigh on performance.

PODD holds a Zacks Rank #2. For 2026, its revenues and EPS are expected to grow 19.8% and 26.3%, respectively. The company’s ...

An FDA warning letter about the wearable company’s blood pressure feature raises questions as the lines between medtech and ...

The GRACE trial suggests that real time continuous monitoring can reduce the risk of having a larger baby in women with ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, aimed at adults who are not using ...

Beta Bionics announced the integration of its iLet Bionic Pancreas with Dexcom's G7 15 Day continuous glucose monitor (CGM).